Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Rating Lowered by BTIG Research

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Rating Lowered by BTIG Research

BTIG Research lowered shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA – Free Report) from a strong-buy rating to a hold rating in a research note published on Thursday, Marketbeat reports. Several other brokerages have also recently weighed in on VRNA. Jefferies Financial Group reiterated a “hold” rating and set a $107.00 price target […]

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc

Open the article to view the coverage from The AI Journal

Biopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy Verona Pharma for $10B; and more

Welcome back to Endpoints Weekly! This week’s recap kicks off with the first installment of an Endpoints News series on pay in biopharma. Senior biopharma correspondent Andrew Dunn collected data on high-paid CEOs, as well ...

Merck to Acquire Verona Pharma in $10B Bid - USA Herald

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its strategy to expand beyond oncology and secure a new growth engine with Verona’s newly approved COPD treatment, Ohtuvayre. The transaction, one of the largest in Merck’s storied history, was unveiled Wednesday, and positions the company to dominate a long-underserved corner of respiratory care, just as its multibillion-dol…